Abstract
Parkinsons disease (PD) is a neurodegenerative disease with limited pharmacologic therapies. Recent animal studies and one large retrospective study have found NSAIDs to be protective against the development of PD. We decided to test this hypothesis by conducting a nested case-control study using the Saskatchewan drug plan database. Entry to the cohort was defined as the first prescription of an antihypertensive agent between 1980 and 1987 and followed until 1999. Cases were defined as those having received three prescriptions for a dopamine agonist within a year. For each case, ten controls were selected matched to the case by age, calendar time and index date. Conditional logistic regression was used to estimate rate ratios adjusting for gender, previous use of arthritis medication and previous antipsychotic use. Current users of NSAIDs had a slightly higher risk of developing PD (RR= 1.49 [95% CI, 1.11-2.01]). This effect was not seen with past users (RR= 1.18 [95% CI, 0.89-1.59]). Based on the results of our study current users of NSAIDs may be at a slightly higher risk of developing PD. More studies are needed to confirm this finding.
Keywords: NSAIDsd, Parkinson's disease
Current Drug Safety
Title: NSAID Use and the Risk of Parkinsons Disease
Volume: 1 Issue: 3
Author(s): Mahyar Etminan and Samy Suissa
Affiliation:
Keywords: NSAIDsd, Parkinson's disease
Abstract: Parkinsons disease (PD) is a neurodegenerative disease with limited pharmacologic therapies. Recent animal studies and one large retrospective study have found NSAIDs to be protective against the development of PD. We decided to test this hypothesis by conducting a nested case-control study using the Saskatchewan drug plan database. Entry to the cohort was defined as the first prescription of an antihypertensive agent between 1980 and 1987 and followed until 1999. Cases were defined as those having received three prescriptions for a dopamine agonist within a year. For each case, ten controls were selected matched to the case by age, calendar time and index date. Conditional logistic regression was used to estimate rate ratios adjusting for gender, previous use of arthritis medication and previous antipsychotic use. Current users of NSAIDs had a slightly higher risk of developing PD (RR= 1.49 [95% CI, 1.11-2.01]). This effect was not seen with past users (RR= 1.18 [95% CI, 0.89-1.59]). Based on the results of our study current users of NSAIDs may be at a slightly higher risk of developing PD. More studies are needed to confirm this finding.
Export Options
About this article
Cite this article as:
Etminan Mahyar and Suissa Samy, NSAID Use and the Risk of Parkinsons Disease, Current Drug Safety 2006; 1 (3) . https://dx.doi.org/10.2174/157488606777934404
DOI https://dx.doi.org/10.2174/157488606777934404 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Foreword:
Current Pharmaceutical Design The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets Soluble Epoxide Hydrolase, a Target with Multiple Opportunities for Cardiovascular Drug Discovery
Current Topics in Medicinal Chemistry Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology Trace Extraction of Metoprolol from Plasma, Urine and EBC Samples Using Modified Magnetic Nanoparticles Followed by Spectrofluorimetric Determination for Drug Monitoring Purposes
Current Pharmaceutical Analysis Bioactivity and Pharmacological Actions of Carbon Monoxide-Releasing Molecules
Current Pharmaceutical Design Overview of Covid-19 Regarding the Cardiovascular Situation in the Light of Current Reports
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Use of Snake Venom Components: A Voyage from Ancient to Modern India
Mini-Reviews in Organic Chemistry Meta-analysis and Approach of the Real Impact of Anorexigenic Drugs in the Obesity in Humans: The Last Five Years of the Randomized Studies
Current Diabetes Reviews Synergic Study of α-Glucosidase Inhibitory Action of Aloin and its Antioxidant Activity with and without Camel β-Casein and its Peptides
Protein & Peptide Letters Editorial (Thematic Issue: Novel Inflammatory Biomarkers in Cardiovascular Disease: From Molecular Mechanisms to Therapeutic Targets (Part-II))
Current Medicinal Chemistry Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design Hemostatic Factors and the Metabolic Syndrome
Current Vascular Pharmacology Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus?
Current Vascular Pharmacology An Update on Peptide Drugs for Voltage-Gated Calcium Channels
Recent Patents on CNS Drug Discovery (Discontinued) Nifedipine Induced Gingival Hyperplasia in Pregnancy: A Case Report
Current Drug Safety Mannose Binding Lectin: A Potential Biomarker for Many Human Diseases
Current Medicinal Chemistry